MedTrace Logo

Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia

NCT07157722 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2025-09-05

No results posted yet for this study

Summary

The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.

Conditions

  • Beta Thalassemia

Interventions

DRUG

Iron chelating intervention

JADENU is indicated for the treatment of chronic iron overload due to blood transfusions.

DRUG

N Acetyl cysteine 600mg

N-acetyl cysteine (NAC) 600 mg will be administered orally once daily for 12 weeks.

DRUG

Alpha Lipoic Acid 600 MG Oral Tablets

Alpha lipoic acid (ALA) 600 mg will be administered orally once daily for 12 weeks.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Sahar M El-Haggar, Professor · Tanta University

  • Tarek M Mostafa, Professor · Tanta University

  • Basma A Mansour, Lecturer · Faculty of Medicine - Mansoura University

  • Mohammed A El hawary, Assistant Professor · Faculty of Medicine - Mansoura University

  • Mahmoud M Elkholy, Teaching Assistant · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-30
Primary Completion
2025-12-30
Completion
2026-01-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07157722 on ClinicalTrials.gov